S-5751

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H31NO4S
Molecular Weight	441.583
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)[C@@H]2C[C@H]1[C@H](NC(=O)C3=CSC4=C3C=C(O)C=C4)[C@@H](C\C=C/CCCC(O)=O)C2

InChI

InChIKey=ZXBHFWFKSIYJEK-MFJOXFORSA-N

InChI=1S/C25H31NO4S/c1-25(2)16-11-15(7-5-3-4-6-8-22(28)29)23(20(25)12-16)26-24(30)19-14-31-21-10-9-17(27)13-18(19)21/h3,5,9-10,13-16,20,23,27H,4,6-8,11-12H2,1-2H3,(H,26,30)(H,28,29)/b5-3-/t15-,16-,20-,23+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11454901 | http://www.shionogi.co.jp/en/company/news/2006/pmrltj0000001d4d-att/e_061027.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21596028

S-5751, an orally active prostanoid DP receptor antagonist, had potent anti-inflammatory effects in guinea pig and sheep asthma models. S-5751 had been in phase II clinical trials by Shionogi for the treatment of bronchial asthma. However, this study was discontinued in 2006.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostanoid DP receptor 15 Target ID: CHEMBL4427 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12773048 \| https://www.ncbi.nlm.nih.gov/pubmed/11454901	Antagonist 2778		0.9 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Asthma 241 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21596028 http://adisinsight.springer.com/drugs/800012090	Primary		Phase I 428	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	P-gp 1537

Drug as perpetrator

Target	Modality	Activity
CYP2D6 1891	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645840#sid=363680345	no
CYP2C9 1819	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=363680345	yes [IC50 1.345 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=363680345	yes [IC50 9.5221 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=363680345	no

Sourcing

Vendor/Aggregator	ID	URL
Axon MedChem	1605	https://www.axonmedchem.com/product/1605
Cayman Chemical	10004030	http://www.caymanchem.com/app/template/Product.vm/catalog/10004030
MolPort	MolPort-042-665-721	https://www.molport.com/shop/molecule-link/MolPort-042-665-721
Toronto Research Chemicals	S080600	https://www.trc-canada.com/product-detail/?CatNum=S080600
eMolecules	44848343	https://orderbb.emolecules.com/search/#?query=44848343

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Rats: S-5751 and pinagladin were orally administered to BN rats three times a day at a maximum dose of 100 mg/kg

Route of Administration: Oral

In Vitro Use Guide

S-5751 inhibited PGD(2)-induced cAMP production in platelet-rich plasma with an IC(50) value of 0.12 uM..

Name

Type

Language

S-5751

Common Name

English

(5Z)-7-((1R,2R,3S,5S)-2-(((5-HYDROXY-1-BENZOTHIEN-3-YL)CARBONYL)AMINO)-6,6-DIMETHYLBICYCLO(3.1.1)HEPT-3-YL)HEPT-5-ENOIC ACID

Systematic Name

English

5-HEPTENOIC ACID, 7-((1R,2R,3S,5S)-2-(((5-HYDROXYBENZO(B)THIEN-3-YL)CARBONYL)AMINO)-6,6-DIMETHYLBICYCLO(3.1.1)HEPT-3-YL)-, (5Z)-

Common Name

English

Code System Code Type Description

FDA UNII

GA0E7U1R52

Created by admin on Fri Dec 15 15:34:37 GMT 2023 , Edited by admin on Fri Dec 15 15:34:37 GMT 2023

PRIMARY

CAS

209268-36-0

Created by admin on Fri Dec 15 15:34:37 GMT 2023 , Edited by admin on Fri Dec 15 15:34:37 GMT 2023

PRIMARY

PUBCHEM

9867949

Created by admin on Fri Dec 15 15:34:37 GMT 2023 , Edited by admin on Fri Dec 15 15:34:37 GMT 2023

PRIMARY

ACTIVE MOIETY


					GA0E7U1R52

S-5751

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11454901 | http://www.shionogi.co.jp/en/company/news/2006/pmrltj0000001d4d-att/e_061027.pdfCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21596028

Originator

Approval Year

Targets

Conditions

Approved Use

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11454901 | http://www.shionogi.co.jp/en/company/news/2006/pmrltj0000001d4d-att/e_061027.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21596028

Drug as perpetrator